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ABSTRACT
Cancer immunotherapy has fundamentally changed the landscape of oncology in recent years and
signiﬁcant resources are invested into immunotherapy research. It is in the interests of researchers and
clinicians to identify promising and less promising trends in this ﬁeld in order to rationally allocate
resources. This requires a quantitative large-scale analysis of cancer immunotherapy related databases.
We developed a novel tool for text mining, statistical analysis and data visualization of scientiﬁc
literature data. We used this tool to analyze 72002 cancer immunotherapy publications and 1469 clinical
trials from public databases. All source codes are available under an open access license.
The contribution of speciﬁc topics within the cancer immunotherapy ﬁeld has markedly shifted over the
years. We show that the focus is moving from cell-based therapy and vaccination towards checkpoint
inhibitors, with these trends reaching statistical signiﬁcance. Rapidly growing subﬁelds include the
combination of chemotherapy with checkpoint blockade. Translational studies have shifted from
hematological and skin neoplasms to gastrointestinal and lung cancer and from tumor antigens and
angiogenesis to tumor stroma and apoptosis.
This work highlights the importance of unbiased large-scale database mining to assess trends in cancer
research and cancer immunotherapy in particular. Researchers, clinicians and funding agencies should be
aware of quantitative trends in the immunotherapy ﬁeld, allocate resources to the most promising areas








Cancer immunotherapy is widely regarded as one of the most
promising approaches for treating metastatic cancer.1 It has
been in the focus of basic, translational and clinical research for
years and signiﬁcant resources have been invested in ﬁnding
new immunotherapy treatments with clinical efﬁcacy.
Anecdotally, most clinicians and researchers in the ﬁeld are
aware that clinical translation has not been equally successful for
each subﬁeld over the last years. For example, it is well-known
that therapeutic vaccines were intensely investigated and shaped
immunotherapy for years but have not yet made a direct clinical
impact. Also, immunotherapy quickly reached clinical applica-
tion in melanoma,2 while gastrointestinal cancer types are still
lagging behind.3 These shifts within the cancer immunotherapy
ﬁeld are highly relevant for clinicians, researchers and funding
agencies. However, until now, these changes have not been
quantiﬁed in a way that allows an unbiased assessment of past
and possible future trends.
In the present study, we quantiﬁed the development of the
cancer immunotherapy ﬁeld from 1986 to 2017 to reveal previ-
ously hidden trends. This type of quantitative and unbiased
analysis is of high interest to researchers and clinicians because
it can guide the allocation of resources for future research and
clinical trials. Speciﬁcally, we focused on the comparison of
treatment approaches, translational research topics and different
tumor entities (organ of the primary tumor, according to the
International Statistical Classiﬁcation of Diseases and Related
Health Problems, ICD-10). Among various types of cancer
immunotherapy,4 we looked at the development of oncolytic
viruses,5 cell-based therapies,6 therapeutic vaccines,7 checkpoint
inhibitors8,9 as well as chemotherapy and radiation therapy.
These treatment types were separately analyzed for all tumor
entities in order ﬁnd out which approaches would be most
promising in speciﬁc entities in the future. To quantify develop-
ments in basic and translational cancer research, we included a
CONTACT Niels Halama, MD niels.halama@nct-heidelberg.de Medical Oncology, National Center for Tumor Diseases (NCT) Im Neuenheimer Feld 460,
Heidelberg 69120, Germany.
Supplemental data for this article can be accessed on the publisher’s website.
© 2018 Jakob Nikolas Kather, Anna Sophie Berghoff, Dyke Ferber, Meggy Suarez-Carmona, Constantino Carlos Reyes-Aldasoroe, Nektarios A. Valous, Rodrigo Rojas-Moraleda, Dirk J€ager, and
Niels Halama. Published with license by Taylor & Francis Group, LLC
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided the original work is properly cited.
ONCOIMMUNOLOGY
2018, VOL. 0, NO. 0, e1444412 (8 pages)
https://doi.org/10.1080/2162402X.2018.1444412
wide range of topics such as the combination of immunotherapy
with stroma10 and cancer-associated ﬁbroblasts,11 angiogene-
sis,12 tumor-speciﬁc antigens,13 neoantigens,14 microbiota,15
drug resistance,16 myeloid cells,17 stem cells,18 epigenetics,19 cell
death and autophagy20,21 as well as metabolism.22 All trends
were analyzed over time, keeping in mind that the ﬁeld was pro-
foundly changed by landmark events such as the ﬁrst clinical
report of effective checkpoint inhibition in cancer patients in
2003.23,24 Inhibitors of immune receptors and ligands are cur-
rently the largest class of approved immunotherapy drugs.25,26
To investigate this subﬁeld in detail, we used a graph-based
approach to visualize which of these checkpoint pathways was
in the focus of research efforts during the last years. Also, this
analysis was used to identify promising combination approaches
to target checkpoint signaling pathways.
In short, we present a novel method for data collection, anal-
ysis and visualization of changing trends in cancer immuno-
therapy from 1986 to 2017 and discuss their implications.
Methods
Database queries
Based on previous literature reviews and other publicly avail-
able resources, we manually curated a list of keywords to enable
the comparison of different tumor entities (organ of the pri-
mary tumor, e.g. brain, breast, sarcoma, etc., complete list in
Suppl. Table 1), treatment approaches (e.g. adoptive cell trans-
fer, oncolytic viruses, checkpoint inhibition, etc., complete list
in Suppl. Table 2), translational research topics (e.g. apoptosis,
stem cells, epigenetics, etc., complete list in Suppl. Table 3) and
cell types (e.g. myeloid, lymphoid, etc., complete list in Suppl.
Table 4). Resources for therapeutic agents were the “NIH: A to
Z List of Cancer Drugs” (retrieved from https://www.cancer.
gov/about-cancer/treatment/drugs on 11 Nov 2017) and all
FDA approvals 2016 and 2017 (retrieved from https://www.fda.
gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.
htm on 11 Nov 2017). Publication data were automatically
mined from MEDLINE, the database of the United States
National Library of Medicine (NLM), and its related search
engine PubMed (https://pubmed.gov). Furthermore, we ana-
lyzed all cancer immunotherapy clinical trials registered in the
ofﬁcial US (https://clinicaltrials.gov) database. PubMed articles
were identiﬁed by the following master search keyword:
(“tumor”[All Fields] OR “tumor”[All Fields] OR “neoplasms”[-
MeSH Terms] OR “neoplasms”[All Fields] OR “cancer”[All
Fields]) AND (“immunotherapy”[MeSH Terms] OR “immuno-
therapy”[All Fields]), in a similar way to a previously published
study.27 For clinical trials, the master keyword was: “cancer
immunotherapy”. For clinical trials, all accessible trial metadata
(title, description and structured information) was downloaded
from respective databases. All database queries were made in
November 2017.
Data analysis
All data analyzes and visualizations were conducted with self-
developed MATLAB scripts (R2017a, MathWorks, Natick, MA,
USA). Data were normalized to the number of total
immunotherapy articles (or trials, respectively) in each year. Data
points were smoothed with a moving average ﬁlter (lowpass ﬁlter
with a coefﬁcient equal to the reciprocal of the time span and a
window size of ﬁve years). All scripts are released open-source and
are available under the following DOI: 10.5281/zenodo.1190620
Trumpet plot
To illustrate the temporal variation of the incidence of keyword
groups, we used the self-developed “trumpet plot”. Normalized
and smoothed timelines were visualized as the height of a “trum-
pet” shape in a 2D. In 3D, the diameter of a cylinder represented
the normalized number of research items in a given year with
time as the vertical axis. Perceptually optimized colour scales
from the “Color Brewer” project were used to visualize data.28
Graph-based analysis and network plot
To investigate the degree of connectivity between similar key-
words in a speciﬁc subﬁeld, we used a graph-based analysis. This
was employed for keywords that represented different immune
checkpoint molecules e.g. PD-1, PD-L1, CTLA-4, CD80, etc. (full
list in Suppl. Table 1). Each keyword was represented by a node
which was visualized as a circle. The size and color of the circle
depicted the number of research items matching this keyword.
The distance between the node and the width of the connecting
edge represented the co-occurrence of two keywords. Logarithmic
scaling was used for the circle size and the edge width. Isolated
nodes without any connection to other nodes were discarded.
Low-abundant nodes (< 10 hits) and edges were also discarded.
Results
Shift from vaccination to checkpoint inhibition in clinical
and translational studies
First, we analyzed the contribution of major treatment types to
the cancer immunotherapy literature. In the PubMed database,
chemotherapy was the most frequent treatment that articles
could be matched to (33% in 2017, Fig. 1A). Checkpoint inhibi-
tion grew signiﬁcantly (indicated by a C in the graphs) from
2015 and was the second most abundant treatment type in
2017. Therapeutic vaccination as a form of cancer immuno-
therapy dropped from position 1 to position 3 in 2017, with sig-
niﬁcant decrease (indicated by a diamond in the graphs)
between 2015 and 2017. These trends were even more pro-
nounced in clinical trials where checkpoint inhibition was
matched in more than 50% of all items in 2017, chemotherapy
being second with 26% and vaccination steadily dropping to
only 9% of clinical trials in 2017 (Fig. 2A). Adoptive cell-based
therapies (including chimeric antigen receptor [CAR] T-cells)
contributed to 15% of all research items in 2017 and to 7% of
all clinical trials (Fig. 1A and Fig. 2A).
Lung and gastrointestinal cancer as prime targets for
immunotherapy
Next, we analyzed cancer immunotherapy research efforts for
each tumor entity. In articles indexed in PubMed,
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hematological neoplasias (hema.) were the prime immunother-
apy target until 2015/2016, but have decreased signiﬁcantly
since, yielding to skin and gastrointestinal (GI) neoplasms
(Fig. 1B). Among the top ﬁve tumor entities (skin, GI, hema.,
respiratory-thoracic [lung] and urinary tract), only lung and GI
showed a signiﬁcant growth in the last ﬁve years (Fig. 1B). This
pattern matched clinical trial data (Fig. 2B) where lung and GI
tumors were the top two cancer entities by far. Again, hemato-
logical neoplasms rapidly (and in one year signiﬁcantly)
decreased in importance; also, sarcoma continuously decreased
in importance over the years (Fig. 2B).
Subsequently, we asked how the different therapy approaches
were reﬂected in each major tumor entity. In the research litera-
ture, checkpoint inhibitors have increased in importance in the
last ﬁve years in all top ﬁve tumor entities (Fig. 1D). The reverse
trend can be observed in vaccination and chemotherapy,
although these still have a large presence. Much more pro-
nounced effects were observed in clinical trials (Fig. 2D): Here,
lung and GI neoplasms were the two most dynamically growing
ﬁeld with growth in skin cancer reaching a plateau and hemato-
logical neoplasms vanishing almost completely.
A transient 1990s interest in myeloid cells left no trace
in the clinic
Cancer immunotherapy aims to (re)invigorate the host immune
response against malignant cells and all types of cancer immuno-
therapy use cells in the tumor microenvironment as their effec-
tors. We analyzed the quantitative contribution of cell types in
the immunotherapy literature. Items related to myeloid cells sig-
niﬁcantly increased its presence in PubMed in the late 1990s
(Fig. 1C), matching a large contribution to clinical trials at that
time (Fig. 2C). However, this transient interest in myeloid cells
plateaued in the scientiﬁc literature and rapidly decreased in clin-
ical trials. Not surprisingly, lymphoid cells were the largest single
group of cells in 2017 in scientiﬁc publications and clinical trials.
Revival of radiation and chemo-immunotherapy
Having analyzed major trends among treatment types, cancer
types and cell types, we looked for non-obvious trends in the
dataset. We found that among treatment types, radiation was
only at position ﬁve in scientiﬁc articles (Fig. 1A) but at position
Figure 1. Trends in PubMed publications from 1986 to 2017 by topic. This Fig. summarizes all PubMed listed cancer immunotherapy articles grouped by category. (A)
Among all cancer immunotherapy articles published in 2017, 33% referred to one or more speciﬁc chemotherapy drugs (bottom shape). This proportion was roughly con-
stant over three decades. Contrariwise, checkpoint inhibition was almost absent before 2010, showing an accelerating growth afterwards. (B) Hematological neoplasms
were the most commonly investigated immunotherapy target until 2014, when they were overtaken by gastrointestinal and skin neoplasms. (C) Among all major cell
types in the tumor microenvironment, myeloid cells were rapidly gaining interest around the year 2000. Afterwards, no signiﬁcant change whatsoever was observed. (D)
Bivariate analysis of treatment types versus cancer types in PubMed cancer immunotherapy publications. Checkpoint inhibition shows a markedly increasing trend (“trum-
pet”) in skin, respiratory, but also urinary tract and gastrointestinal cancer. (A-C) C signiﬁcant rise of growth rate within one year (anomaly >95%),  signiﬁcant decrease
of one-year growth rate (anomaly< 5%).
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three in clinical trials (Fig. 2A). In both cases, the growth rate in
2017 signiﬁcantly exceeded that of previous years. These trends
followed a decrease during the early 2000s in radiation therapy
in articles and clinical trials (Fig. 1A and Fig. 2A). Based on
these data, we conclude that we are currently witnessing a revival
of the use of radiation in cancer immunotherapy.
We hypothesized that other non-obvious trends might be
hidden in treatment combinations and therefore analyzed co-
occurrence of treatment types in clinical trials (Fig. 3A). In this
analysis, the diagonal of the matrix corresponds to Fig. 2A. We
found that the only markedly increasing treatment combina-
tion is chemotherapy plus checkpoint inhibition (Fig. 3A). In
contrast, virtually no registered clinical trials investigate the
combinations vaccination plus checkpoint inhibition or adop-
tive cellular therapy plus checkpoint inhibition.
Stroma and apoptosis in gastrointestinal cancer
Our automatic approach for database mining allowed for an
analysis of translational research topics per tumor type. For clar-
ity, only a part of this analysis is shown in Fig. 3B. We found
that among translational research topics in immunotherapy
articles, angiogenesis is decreasing in importance in all major
cancer entities. In contrast, apoptosis (and other forms of cell
death as well as autophagy) is rapidly gaining ground in GI,
lung and skin cancer (Fig. 3B). Interestingly, the quantitative
contribution of cancer stroma to immunotherapy articles is stag-
nating or decreasing in all major cancer entities except GI cancer
(Fig. 3B). Complementing our above-described ﬁnding that GI
cancer is one of the most dynamically growing research topics
in immunotherapy, we conclude that especially apoptosis and
stroma are promising subﬁelds in this entity.
Translational activities vary considerably between tumor
types
Our next step was to examine the following question: how were
preclinical research efforts, measured by the number of indexed
items on PubMed, translated into clinical trials? To give a speciﬁc
answer for all therapy types and major cancer entities, we compared
timelines for multiple keywords in PubMed and clinical trial data-
bases. We analyzed the number of clinical trials in the last ﬁve years
(2012–2016) and normalized these numbers to the respective num-
ber of PubMed research items in the preceding ﬁve years. Among
Figure 2. Trends in clinical trials from 2000 to 2017 per topic. This Fig. summarizes all registered clinical trials of cancer immunotherapy grouped by category. (A) Immune
checkpoint inhibition has rapidly become the most common therapy approach between 2010 and 2017. At the same time, vaccination approaches have greatly dimin-
ished, being subject to only 9% of clinical immunotherapy trials in 2017. (B) As in PubMed publications, hematological neoplasms have markedly lost ground, yielding to
gastrointestinal and respiratory neoplasms in recent years. (C) Among all major cell types in the tumor microenvironment, myeloid cells were in the focus of research
interest around 2000, diminishing afterwards and only being investigated in 2% of immunotherapy clinical trials in 2017. (D) Bivariate plot of treatment types versus can-
cer types in cancer immunotherapy clinical trials. Checkpoint inhibition shows an increasing trend (“trumpet”) in respiratory and gastrointestinal cancer. (A-C) C signiﬁ-
cant rise of growth rate within one year (anomaly >95%),  signiﬁcant decrease of one-year growth rate (anomaly< 5%).
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all therapy types, immune checkpoint inhibition stood out in terms
of translational efﬁciency with close to 0.2 clinical trials per research
paper in the reference periods (Fig. 4A). Looking at various tumor
entities, the differences in translational efﬁciency were not as large
(Fig. 4B). Highest translational efﬁciency was visible in immuno-
therapy of gastrointestinal and respiratory neoplasms while a low
translational efﬁciency was seen in hematological malignancies with
just 0.02 clinical trials per article (Fig. 4B).
Another way of comparing the translational efﬁciency of
immunotherapy subﬁelds is to look at the development of clini-
cal phase 1/2/3 trials over time. We matched all cancer
immunotherapy trials registered at clinicaltrials.gov and all
PubMed articles (when applicable) to one or more clinical
phases. In the timelines in Fig. 5A, a small and stable percent-
age of PubMed articles can be matched to any clinical trial
phase over time. Within registered clinical trials (Fig. 5B),
phase 1 and 2 trials are slowly increasing with phase 3 trials
decreasing at the same time. However, in general, no pro-
nounced trends were visible in this analysis. This picture
changed markedly when analyzing clinical trials for each major
tumor entity (Fig. 5C): Phase 1 and 2 trials were rapidly
increasing in gastrointestinal and lung cancer in the last ﬁve to
Figure 3. Emerging immunotherapy paradigms. (A) Co-occurrence of cancer immunotherapy treatment approaches in clinical trials between 2000 and 2017. On the diag-
onal, the development of individual treatment approaches is shown with checkpoint inhibition displaying a rapid increase. Off the diagonal, treatment combinations are
shown with chemotherapy and checkpoint inhibition being the most common and rapidly growing combination. (B) This bivariate plot shows cancer immunotherapy
trends grouped by translational research topics and major cancer types based on all PubMed publications between 1986 and 2017. Among signalling, stroma, apoptosis
and angiogenesis, apoptosis is the most rapidly growing topic in all major cancer entities except hematological neoplasms. Stroma and signalling are most rapidly increas-
ing in gastrointestinal cancer.
ONCOIMMUNOLOGY e1444412-5
Figure 4. Translational efﬁciency. We asked how the number of research publications inﬂuences the number of clinical trials in subsequent years. To this end, we analyzed
PubMed articles for speciﬁc ﬁelds in a ﬁve-year period (2006–2011) and evaluated the number of matching US-registered clinical trials in the following ﬁve years (2012–
2016). This yields a measure of translational efﬁciency (clinical trials per research publication). (A) Among therapy types, immune checkpoint inhibitors had the highest
translational efﬁciency with approximately 0.2 trials per publication. Scientiﬁc ﬁndings in vaccination and cell-based therapy were not efﬁciently translated to the clinic.
(B) Among major tumor entities, translational efﬁciency was highest for gastrointestinal tumors and lowest for hematological and lymphoid malignancies (hema.). It is in
the interest of the research community to increase translational efﬁciency in these low-performing ﬁelds.
Figure 5. Clinical trial phases. This Fig. shows the development of clinical trials in phase 1/2/3 over time. (A) PubMed articles matching any clinical phase. Only a fraction
of PubMed listed articles can be matched to a clinical phase and the proportions between the phases have not changed signiﬁcantly in the last 20 years. (B) Clinical trials
matching any clinical phase, ordered by group size, from bottom to top: phase 2, phase 1, phase 3. Some trials could be matched to multiple phases so that the percen-
tages in 2017 do not necessarily add up to 100%. Phase 2 trials are most abundant and phase 1 trials are slowly growing, albeit not signiﬁcantly. (C) In stark contrast to
the slow overall growth dynamic of clinical trials in the above panels, this panel shows marked changes in clinical trials per cancer entity over time. In gastrointestinal can-
cer and respiratory-thoracic cancers, phase 1 and 2 trials are currently showing pronounced increase. (ACB) C signiﬁcant rise of growth rate within one year (anomaly
>95%),  signiﬁcant decrease of one-year growth rate (anomaly < 5%).
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ten years, but not in other major tumor entities. These data
match our above-mentioned ﬁnding that GI and lung cancer
are the most translationally active ﬁelds as compared to skin
cancer, hematological neoplasias and other major cancer types.
Immune-checkpoint networks
Based on above-described results we concluded that checkpoint
inhibition makes the largest quantitative contribution to research
papers and clinical trials in immunotherapy research and is also
the most efﬁcient subﬁeld in terms of clinical translation. There-
fore, we performed a more speciﬁc analysis and asked how the
contribution and intertwining of immune checkpoint molecules
and drugs developed over time. Based on our timeline analysis
(Fig. 1A) we estimated that around 2011, the increase in check-
point inhibition publications started. We therefore used the fol-
lowing time frames, 1986–2010 and 2011–2016, to compare co-
occurrence of checkpoint molecules in PubMed articles. These
comparisons are shown in Fig. 6 as network plots. In 1986 to
2010, CD80 had the highest prevalence (Fig. 6A) and a cluster
around CD80/CD86/CD28/CD40L/CD40 dominated the
immune checkpoint landscape in PubMed articles. In 2011 to
2016, a marked change was evident and PD-1/PD-L1, which were
previously in the periphery of the network, and CTLA-4, which
remained in the center, made by far the largest contribution
(Fig. 6B). Interestingly, CD80 (B7–1) still occupied a central “hub”
position, linking two distant parts of the network with each other.
Discussion
Tumor immunotherapy research is a dynamically evolving ﬁeld
and has undergone profound changes in the last three decades.
While these developments might be implicitly known by
researchers who have been deeply involved in the ﬁeld for a
long time, they are probably not apparent to most clinicians
and scientists who are now confronted with immunotherapy.
Moreover, researchers and clinicians working in the ﬁeld may
have cognitive biases and therefore may not be aware of well
and poorly performing subﬁelds of immunotherapy research.
In this paper, we presented a quantitative, objective and com-
prehensive analysis of the changes in tumor immunotherapy
research over time which can serve as a rational basis for fur-
ther discussions.
Skin cancer (mainly melanoma) was the ﬁrst tumor entity to
have effective immunotherapy agents approved and is still in
the focus of research papers. Yet, clinical trials now focus on
gastrointestinal and respiratory cancers, two major disease clas-
ses associated with signiﬁcant morbidity and mortality. Trans-
lational research means that new knowledge should be
effectively transferred to the clinic.29 Researchers pursuing
translational research will therefore meet this aim more easily
in an area where translation has been shown to be feasible. By
extrapolating these current trends, translational research efforts
would be most fruitful in gastrointestinal and respiratory
cancer.
As a word of caution, we should also acknowledge that
many unexpected breakthroughs come from previously unno-
ticed areas in biomedical research. Also, not all ongoing
research efforts might be reﬂected by PubMed publications or
registered clinical trials. Yet, for the tedious process of using
research results from the laboratory to improve treatments in
the clinic, a structured and objective projection of future trends
can be very useful. Our data-driven analytics approach provides
a starting basis for such endeavors.
Figure 6. Graph-based analysis of immune checkpoints. In these graphs, the distance between two nodes denotes the co-occurrence while the color of the bubble
denotes the frequency of occurrence (bubble sizes are log occurrence). (A) Before 2011, a cluster around CD80/CD86/CD40/CD28 dominated immune checkpoint research.
(B) This has fundamentally changed since 2011: The ﬁeld is now dominated by PD-1/PDL1, with CTLA-4 as a bystander. The number of relevant immune checkpoints has
markedly increased. CD80 still occupies a central position in the network, linking the CD40/CD86/CD40L cluster with PD1/PD-L1/CTLA-4. TIM3 and OX40 have also moved
closer to the network’s core, indicating an increasing importance despite few absolute hits.
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